Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
- Triggering Signals of BRCA1 Breast Cancer (K Kessenbrock)
- Testing Diverse Groups Finds New Breast Cancer Genes (L Teras)
- Black Women & Genetic Testing (J Palmer)
- Women 65+ & Genetic Tests for Breast Cancer Risk (L Teras)
- High-Risk Genes and Screening (A Patel)
- New Risk Calculation May Affect Breast Cancer Screening (L Teras)
- Black Men and Breast Cancer (H Sung)
- Platelets May Help Breast Cancer Spread (E Battinelli)
- Natural Killer Cells & TNBC (R. Chakrabarti)
- Improving Chemotherapy (O Sahin)
- Combo Treatment for TNBC (K Varley)
- Treatments Attack Cell Division (A Holland)
- ER+ Treatment in Mice (P Kenny)
- Blood DNA Monitors Metastasis Treatment (H P Ji)
- PTK6 Gene as Treatment Target (H Irie)
- Time-Lapse Cell Movies (S Spencer)
- 3D Mini Breast Tumors May Help ID New Cancer Treatments
- AI Tool Improves Breast Cancer Prognosis Accuracy
- Exercise & Sitting Time (E. Rees-Punia)
- Cancer Risk Factors in LGBTQ Populations (B. Charlton)
- CPS-3 Disparities Studies
- Cancer Disparities in the US (F. Islami)
- Housing Assistance and Mammograms (H Lee)
- Clinical Trial Treatment Cost App (L Hamel)
- Podcasts, TheoryLab
- Patients Health Insurance Tool (M. Politi)
- Breast Cancer Treatment in Ethiopia (A. Jemal)
- Better Survival Requires Better Insurance (J Zhao)
- Medicaid Eligibility Limits (J Zhao)
- New Treatment for Neuroblastoma (A Heczey)
- Oncogenic Fusions AML (S Meshinchi)
- Genetic Risks (L Teras)
- New Medulloblastoma Drugs (J Rodriguez-Blanco)
- Potential New Hope for MLL (J Grembecka)
- Increase in Brain Tumor Diagnosis (K Miller)
- Longer Life Expectancy for Survivors (J Yeh)
- Potential Target for New Osteosarcoma Drugs (C Benavente)
- At-Home Chemo for Children with HR ALL (L Ranney)
- Childhood Cancer Research Landscape Report
- Tumor-Infiltrating Neutrophils (R. Sumagin)
- New Epigenetic Target (K Rai)
- Extra Chromosomes (Aneuploidy) Effect on Cancer (J. Sheltzer)
- Discovery of a New Biomarker Is the First Step to New Treatment (C. Maher)
- Designer Virus Targets and Kills CRC Cells in Mice (S. Warner)
- Tiny Sensor in Mice May Find Cancer That's Trying to Spread (L. Hao)
- Targeting a Protein “Turned on” by Mistake (N. Gao)
- Spatial Map Intestines (J Hickey)
- CRC Treatment Podcasts
- Keto Molecule & Colorectal Cancer (M Levy)
- Availability of Healthy Food (L Tussing-Humphreys)
- 45 Min/Day of Physical Activity (A Minihan)
- Fewer than 10K Steps/Day (A Patel)
- Yogurt & Cheese & ER- Breast Cancer (M McCullough)
- Stage 2 Clinical Trials for New Endometrial Cancer Drug (V Bae-Jump)
- Hard-to-Starve Pancreatic Cancer Cells (N Kalaany)
- Coffee Risks for Colorectal Cancer (C Um)
- Food Parasite & Brain Cancer Risk (J Hodge)
- Exercise & Quality of Life in Older Survivors (E Rees-Punia)
- 21 Metabolites Linked with Breast Cancer (Y Wang)
- Replacing Sitting May Affect Weight (E Rees-Punia)
- CPS-3 Researchers Ask What People Eat and Check Urine Samples (Y Wang)
- Video Games Motivate Exercise? (E. Lyons)
- Food Choices and Colon Cancer Risk (P. Chandler)
- Race, Exercise & Breast Cancer (C. Dallal)
- Diet with Colorectal Cancer (M. Guinter)
- Biomarkers May Improve Prediction (Y Wang)
- Kickstart NSCLCs Clinical Trials (L. Eichner)
- Mapping Mitochondria's “Dance” (D. Shackleford)
- E-Cig Use Ages 18 to 29 (P. Bandi)
- Stopping Smoking Earlier in Life (F Islami)
- Most with Lung Cancer Smoked (A Jemal)
- Furthering Lung Cancer Screening & Equity (S Fedewa)
- Mouse Lung Organoids for Research (C Kim)
- Quality of Life for Lung Cancer Survivors (J Temel)
- Precision Therapies for NSCLC (P Jänne)
- Cancer Deaths from Smoking (F Islami)
- Lung Cancer Surgery Disparities (A Jemal)
- BRG1-Deficient Lung Cancers (C Kim)
- Yoga for Couples with Lung Cancer (K Milbury)
- Metabolic Differences as New Drug Targets (A Marcus)
- CPS-II & CPS-3 Inform About Risks of Ovarian Cancer
- Machine Learning & Glowing Nanosensors (D Heller)
- Ovarian Cancer May Start in Fallopian Tube Cells (K Lawrenson)
- New Gene Linked with Deadliest Type (C Han)
- Gene-Testing Tools May Personalize Care (A Sood)
- Chromosome-Hoarding Ovarian Cancer Cells & Treatment (J Sheltzer)
- Nanoparticles as Drug Delivery for Metastases (X Lu)
- Turning Off 2 Proteins to Slow HGSC (P Kreeger)
- Targeted Light Therapy in Mice (M Bai)
- Nanoparticles, CAR T, and CRISPR (M Stephan)
- Endometriosis & Ovarian Cancer in Mice (M Wilson)
- Ovarian Cancer Special Section
- UV Exposure, Melanoma, & Dark Skin Types (A. Adamson)
- Melanoma and Lipid Droplets (R. White)
- Zebrafish and Acral Melanoma (R. White)
- T-Cell Lymphoma and PD1 (J. Choi)
- New Drug Destroys Cancer-Causing Protein (C. Crews)
- Virus & Merkel Cell Skin Cancer (R. Wang)
- Non-Genetic Drug Resistance (S. Spencer)
- Hijacking the Body's Sugar (R. Wang)
- Telling about High Risk (P. Kanetsky)
- Brain Metastasis and Alzheimer’s (E. Hernando)
- Exhausted Melanoma "Killer" Cells (W. Cui)
Survival Rates for CRC Remain Low in Sub-Saharan Africa
Researchers find a country’s Human Development Index (HDI) affects colorectal cancer (CRC) outcomes even more than stage at diagnosis.
The Challenge
Colorectal cancer (CRC) is on the rise in sub-Saharan Africa. Reasons include many areas experiencing rapid socioeconomic development, urbanization, and lifestyle changes.
Previous studies have found that survival after a diagnosis of CRC is poor in sub-Saharan Africa mostly because of inadequate access to cancer screening and treatment.
But those studies used data from individual hospitals. There’s limited research using population-based survival data for CRC care in sub-Saharan Africa. Such studies are more relevant for a broad population and needed to guide and assess effectiveness of colorectal care programs.
The Research
To help fill that gap, Ahmedin Jemal, DVM, PhD, senior vice president, Surveillance & Health Equity Science at the American Cancer Society (ACS), worked with collaborators from Emory University in Atlanta, France, Germany, and 11 countries in sub-Saharan African (see map) to review data from 13 international, population-based cancer registries.
The green region is sub-Saharan Africa. The countries labeled provided cancer registry data for this study.
They examined age, stage at diagnosis, and survival at 1, 3, and 5 years after diagnosis based on country-level Human Development Index (HDI). HDI is determined by the country’s average life expectancy at birth, years of education, and income per person (per capita).
The authors reported their findings in a paper published in Cancer Epidemiology. They estimated that the relative survival rate at 5 years in these registry populations was 48%. That means that 5 years after being diagnosed, people who have CRC are, on average, about 48% as likely to be living as people who don’t have that cancer. In the United States, the relative survival rate at 5 years is 64% for colon cancer and 67% for rectal cancer.
Poorer survival was linked with a:
- Later stage at diagnosis
- Lower HDI
- Diagnosis at an age younger than 50 or older than 70
We randomly selected 1,707 people with colorectal cancer between 2005 and 2015 from 13 population-based cancer registries in sub-Saharan Africa. We found that survival for colorectal cancer remains low in sub-Saharan African countries, though estimates vary considerably by Human Development Index (HDI). People living in a low-HDI country had twice the risk of death than those in a high-HDI country, even when colorectal cancer was diagnosed at an early stage.”
Ahmedin Jemal, DVM, PhD
Surveillance and Health Equity Science
American Cancer Society
Jemal and his fellow researchers found the 5-year relative survival rate from people with CRC from countries with a low HDI was 31%. That’s lower than the 5-year survival rate in Europe during the late 1970s, when it was 40% for colon cancer and 38% for rectal cancer.
Even when diagnosed at an early stage, the risk of death among people with colorectal cancer is more than 2 times as high in low-HDI countries compared with high-HDI countries.
The authors note that the link between lower economic development and poorer cancer outcomes likely reflects the:
- Country health system’s strength, accessibility, and ability to provide timely and appropriate diagnoses and treatments
- Population's level of health awareness
Why It Matters
Jemal’s results suggest that improving access to prevention, screening, and early treatments in sub-Saharan Africa will help improve survival for colorectal cancer and other cancer types. Strengthening healthcare systems in this region is especially important because the incidence of colorectal cancer continues to rise in sub-Saharan Africa.